Fructose-1,6-bisphosphatase as a therapeutic target for type 2 diabetes

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 2, 2007, Pages 103-109

  van Poelje, Paul D ^a   Dang, Qun ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING CARBOHYDRATE METABOLISM; ANTIDIABETIC AGENT; CP 316819; CS 917; FRUCTOSE BISPHOSPHATASE; FRUCTOSE BISPHOSPHATASE INHIBITOR; GLIBENCLAMIDE; GLUCOSE; INSULIN SECRETAGOGUE; INSULIN SENSITIZING AGENT; LACTIC ACID; MB 05032; MB 07803; METFORMIN; PIOGLITAZONE; PLACEBO; PSN 357; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LACTATE BLOOD LEVEL; LACTICEMIA; MONOTHERAPY; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 41949122574     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.10.003     Document Type: Review

References (39)

1. Olefsky J.M. Insulin resistance and the pathogenesis of non-insulin dependent diabetes mellitus: cellular and molecular mechanisms. In: Ostenson O.G., et al. (Ed). New Concepts in the Pathogenesis of NIDDM (1993), Plenum Press 129-150
2. Hundal R.S., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000) 2063-2069
3. 13C-NMR. Science 254 (1991) 573-576
4. Landau B.R., et al. Contributions of gluconeogenesis to glucose production in the fasted state. J. Clin. Invest. 98 (1996) 378-385
5. Gastaldelli A., et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50 (2001) 1807-1812
6. 13C nuclear magnetic resonance study. J. Clin. Invest. 90 (1992) 1323-1327
7. Wajngot A., et al. Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50 (2001) 47-52
8. Cherrington A.D. Banting lecture: control of glucose uptake and release by the liver in vivo. Diabetes 48 (1999) 1198-1214
9. Leroith D., et al. Diabetes Mellitus. A Fundamental and Clinical Text (1996), Lippincott - Raven
10. Jeng C.Y., et al. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43 (1994) 1440-1444
11. Maggs D.G., et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128 (1998) 176-185
12. Bavenholm P.N., et al. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 50 (2001) 1449-1454
13. Mackay P., et al. Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d-arabinitol in glucagon-challenged rats and dogs and in diabetic ob/ob mice. Diabetes Obes. Met. 5 (2003) 397-407
14. Martin W.H., et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1776-1781
15. Treadway J.L. New targets for glycemic control: glycogen phosphorylase inhibitors. Proceedings of the 65th Scientific Sessions of the American Diabetes Association. San Diego, CA, USA, 10-14 June (2005)
16. Burgess S.C., et al. Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. J. Biol. Chem. 279 (2004) 48941-48949
17. Foley L.H., et al. Modified 3-alkyl-1,8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett. 13 (2003) 3607-3610
18. Parker J.C., et al. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphatase. Diabetes 47 (1998) 1630-1636
19. Gitzelmann R., et al. In: Scriver, et al. (Ed). The Metabolic and Molecular Basis of Inherited Disease (1995), McGraw-Hill
20. Kodama H., et al. The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic gluconeogenesis and hyperglycemia in genetically diabetic (C57BL/DsJ-db/db) mice. Jpn. J. Pharmacol. 66 (1994) 281-287
21. Lamont B.J., et al. Expression of human fructose-1,6-bisphosphatase in the liver of transgenic mice results in increased glycerol gluconeogenesis. Endocrinology 147 (2006) 2764-2772
22. Natali A., and Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49 (2006) 434-441
23. Cryer D.R., et al. Comparative outcomes study of metformin intervention versus conventional approach. Diabetes Care 28 (2005) 539-543
24. El-Maghrabi M.R., et al. Isolation of a human liver fructose 1,6-bisphosphatase cDNA and expression of the protein in Escherichia coli. J. Biol. Chem. 268 (1993) 9466-9472
25. Pilkis S.J. Hepatic gluconeogenesis/glycolysis: regulation and structure/function relationships of substrate cycle enzymes. Annu. Rev. Nutr. 11 (1991) 465-515
26. Ke H., et al. Conformational transition of fructose-1,6-bisphosphatase: structure comparison between the AMP complex (T form) and the fructose 6-phosphate complex (R form). Biochemistry 30 (1991) 4412-4420
27. Pilkis S.J., et al. The effect of arabinose 1,5-bisphosphate on rat hepatic 6-phosphofructo-1-kinase and fructose-1,6-bisphosphatase. Biochem. Biophys. Res. Commun. 138 (1986) 159-166
28. Wright S.W., et al. 3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg. Med. Chem. Lett. 13 (2003) 2055-2058
29. von Geldern T.W., et al. Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphosphatase with a distinct binding mode. Bioorg. Med. Chem. Lett. 16 (2006) 1811-1815
30. Erion M.D., et al. MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7970-7975
31. van Poelje P.D., et al. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 55 (2006) 1747-1754
32. Erion M.D., et al. Fructose 1,6-bisphosphatase inhibition improves oral glucose tolerance and enhances the antidiabetic action of glyburide in the Zucker diabetic fatty rat. Diabetologia 47 (2004) (Abstract 0796)
33. van Poelje P.D., et al. Combination therapy with pioglitazone and a fructose-1,6-bisphosphatase inhibitor (MB06322) improves glycemic control and lactate homeostasis in male Zucker diabetic fatty (ZDF) rats. Diabetologia 49 (2006) (Abstract 0852)
34. Lee W.N., et al. Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E425-E432
35. Walker J., et al. Safety and tolerability of single doses of CS-917, a novel gluconeogenesis inhibitor, in normal male volunteers. Diabetes 55 (2006) (Abstract 2002-PO)
36. Walker J., et al. Safety, tolerability and pharmacodynamics of multiple doses of CS-917 in normal volunteers. Diabetes 55 (2006) (Abstract 2003-PO)
37. Triscari J., et al. Multiple ascending doses of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes treated for 14 days. Diabetes 55 (2006) (Abstract 444-PO)
38. Bruce S.R., et al. Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes. Diabetologia 49 (2006) (Abstract 0037)
39. Treadway J.L., et al. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 10 (2001) 439-454